Leptin receptor expression in neoplastic and normal ovarian and endometrial tissue

Purpose: The objective of this study was to investigate the expression of leptin receptors in benign and malignant tumors of the ovaries and endometrium and its association with body mass index (BMI). Methods: Histological uterine and ovarian samples of normal and neoplastic tissue from 35 patients aged 37-72 years were examined for the expression of leptin receptors with the method of RT-PCR. T. Results: A BMI > 30 was correlated with increased expression of leptin receptors. Both Ra and Rb receptors were expressed in normal and neoplastic tissues. A statistically significant difference in leptin receptor expression was detected between normal and neoplastic tissue, with expression being around 5-fold higher in neoplatic tissue. Conclusion: Endometrial neoplasms and long leptin isoform receptor expression were associated with an increased BMI. A role of long isoform in endometrial carcinogenesis is proposed.

Leptin; Receptor; Cancer; Endometrium; Ovary

[1] Tanaka T., Umesaki N.: “Leptin regulates the proliferation and apoptosis of human endometrial epithelial cells”. Int. J. Mol. Med., 2008, 22, 683.

[2] Calabro P., Yeh E.T. : “Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ”. Subcell. Biochem., 2007, 42, 63.

[3] Petridou E., Papadiamantis Y., Markopoulos C., Spanos E., Dessypris N., Trichopoulos D.: “Leptin and insulin growth factor I in relation to breast cancer (Greece)”. Cancer. Causes Control., 2000, 11, 383.

[4] Koda M., Sulkowska M., Wincewicz A., Kanczuga-Koda L., Musiatowicz B., Szymanska M., Sulkowski S.: “Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer”. Ann. N. Y. Acad. Sci., 2007, 1095, 90.

[5] Sharma D., Saxena N., Vertino P., Anania F. : “Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways”. Endocrine-Related Cancer, 2006, 13, 629.

[6] Petridou E., Belechri M., Dessypris N., Koukoulomatis P., Diakomanolis E., Spanos E., Trichopoulos D.: “Leptin and body mass index in relation to endometrial cancer risk”. Ann. Nutr. Metab., 2002, 46, 147.

[7] Anderson A.S., Caswell S. : “Obesity management-an opportunity for cancer prevention”. Surgeon., 2009, 7, 282.

[8] Purdie D.M., Bain C.J., Webb P.M., Whiteman D.C., Pirozzo S., Green A.C.: “Body size and ovarian cancer: case-control study and systematic review (Australia)”. Cancer Causes Control., 2001, 12, 855.

[9] Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M.: “Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies”. Lancet., 2008, 371, 569.

[10] Yuan S.S., Tsai K.B., Chung Y.F., Chan T.F., Yeh Y.T., Tsai L.Y. et al.: “Aberrant expression and possible involvement of the Ob receptor in endometrial cancer”. Gynecol. Oncol., 2004, 92, 769.

[11] Kitawaki J., Koshiba H., Ishihara H., Kusuki I., Tsukamoto K., Honjo H.: “Expression of leptin receptor in human endometrium and fluctuation during the menstrual cycle”. J. Clin. Endocrinol. Metab., 2000, 85, 1946.

[12] Carino C., Olawaiye A.B., Cherfils S., Serikawa T., Lynch M.P., Rueda B.R., Gonzalez R.R.: “Leptin regulation of proangiogenicmolecules in benign and cancerous endometrial cells”. Int. J. Cancer., 2008, 123, 2782.